About Cyclin E1 (CCNE1) MGDs Cyclin E1 (CCNE1) is a critical driver of cell cycle progression and cell proliferation that is frequently amplified or overexpressed in solid malignancies including ...

Key Takeaways Zentalis Pharmaceuticals progresses with azenosertib in the DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer, aiming for FDA approval by 2026. Part 2a of the trial ...

BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (GLUE) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines ...

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer Published Jan 29, 2025 7:00am EST ...

FDA grants Fast Track Designation for azenosertib in Cyclin E1 positive cancer. Clinical data update to follow on January 29, 2025. Quiver AI Summary Zentalis Pharmaceuticals announced that the U ...

Zentalis Pharmaceuticals has won a U.S. Food and Drug Administration fast-track designation for its lead product candidate azenosertib for certain cancer patients with high levels of the Cyclin E1 ...

Cyclin-dependent kinases (CDK) are serine/threonine kinases that act as regulatory enzymes involved in cell proliferation. The dysregulation of CDK activity occurs through overexpression of cyclin E1, ...

Cedilla Therapeutics Inc. has synthesized cyclin-dependent kinase 2 (CDK2)/cyclin E1 inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, Cushing syndrome, Alzheimer's ...

Results In the PALOMA-3 trial, 302 patients had tumor tissue analyzed (palbociclib arm, 194 patients; placebo arm, 108 patients). Palbociclib efficacy was lower in patients with high versus low cyclin ...